Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of solid tumors. The company's product candidate includes CTIM-76, a Claudin 6 (CLDN6) x CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. It has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. The company was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.…
Context Therapeutics Reports Third Quarter 2026 Financial Results and Pipeline Progress
Context Therapeutics (NASDAQ: CNTX) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 15 employees.
The shares were at 0.1600 USD on 20 November 2026, down 85.7% over 52 weeks. Its 52-week range is 0.1526 USD to 3.620 USD: the price is 95.6% below the high and 4.8% above the low.
Its market capitalisation is 14.70M USD.
Context Therapeutics reports return on equity of -59.7% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 34.20M USD. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health.